Baxter Healthcare Corporation has secured FDA approval for intravenous sodium bicarbonate, a critical product for the acute management of metabolic acidosis. The approval bolsters the company’s critical care portfolio and provides market assurance through the expiration of Bio-Crossline’s exclusivity rights.